Melatonin is an indoleamine with potent multifunctional biological and pharmacological effects, both receptor dependent and receptor-independent effects, including
antioxidant, anticancer, antitumor, anti-inflammatory, anti-aging, anti-diabetic,
antiviral, neuroprotective activities.
Melatonin mitigates tissue injury via modification of abnormalities in redox status and other
biochemical markers. At the molecular level, the biological and pharmacological activities of
melatonin are attributed to the inhibition of nuclear factor-κappa beta (NF-κβ), c-Fos over expression and down-regulation of matrix metalloproteinases-3 (MMP-3), which are regulators of pro-inflammatory and pro-fibrotic
cytokines. There are numerous scientific reports on the therapeutic potential of
melatonin in treatment of
asthma,
respiratory diseases for
infections,
chronic obstructive pulmonary disease,
lung cancer, pleural cavity diseases, as well as vascular
pulmonary disease. In the present communication, we systematically review the therapeutic potential of
melatonin in the treatment of
respiratory diseases along with its molecular mechanism of actions.